CYP21A2 mutations are relatively common, particularly among certain populations. The prevalence of CAH due to 21-hydroxylase deficiency is estimated to be 1 in 10,000 to 1 in 15,000 live births. Carrier frequency is higher, meaning many people carry a single copy of the mutated gene without showing symptoms.
